Terms: = Lymphoma AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
2715 results:
1. car T-Cell Immunotherapy in Minority Patients with lymphoma.
Ghilardi G; Williamson S; Pajarillo R; Paruzzo L; Chen L; Grady C; Doucette A; Nemecek E; Gabrielli G; Barta SK; Svoboda J; Chong EA; Yelton R; Nasta SD; Landsburg DJ; Ugwuanyi O; Chen AI; Schachter L; White G; Ballard HJ; Weber E; Curley C; Porter DL; Garfall AL; Hwang WT; Guerra CE; Maziarz RT; Schuster SJ; Ruella M
NEJM Evid; 2024 Apr; 3(4):EVIDoa2300213. PubMed ID: 38776868
[TBL] [Abstract] [Full Text] [Related]
2. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
Li H; Wang Y; Liu R; Li X; Zhang P; Chen P; Zhao N; Li B; Wang J; Tang Y
J Transl Med; 2024 May; 22(1):482. PubMed ID: 38773607
[TBL] [Abstract] [Full Text] [Related]
3. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Clin Exp Med; 2024 May; 24(1):105. PubMed ID: 38771501
[TBL] [Abstract] [Full Text] [Related]
4. Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.
Katsin M; Shman T; Migas A; Lutskovich D; Serada Y; Khalankova Y; Kostina Y; Dubovik S
Front Immunol; 2024; 15():1380451. PubMed ID: 38765003
[TBL] [Abstract] [Full Text] [Related]
5. [T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?].
Bücklein V; von Tresckow B; Subklewe M
Dtsch Med Wochenschr; 2024 May; 149(11):630-637. PubMed ID: 38749439
[TBL] [Abstract] [Full Text] [Related]
6. Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
Jiang Y; Feng D; Zhu J; Wei D; Zhao C; Liu H; Shao S; Wang C
Front Immunol; 2024; 15():1381308. PubMed ID: 38745670
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive analysis of the efficacy and safety of car T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
[TBL] [Abstract] [Full Text] [Related]
8. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract] [Full Text] [Related]
9. Stealth transgenes enable car-T cells to evade host immune responses.
Grauwet K; Berger T; Kann MC; Silva H; Larson R; Leick MB; Bailey SR; Bouffard AA; Millar D; Gallagher K; Turtle CJ; Frigault MJ; Maus MV
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724463
[TBL] [Abstract] [Full Text] [Related]
10. Off-the-shelf car-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
Kang Y; Li C; Mei H
J Hematol Oncol; 2024 May; 17(1):29. PubMed ID: 38711046
[TBL] [Abstract] [Full Text] [Related]
11. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.
Eigendorff F; Filimonova I; Scholl S; Sayer-Klink A; Rummler S; Kunert C; Pietschmann K; Wittig A; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2024 May; 150(5):224. PubMed ID: 38693452
[TBL] [Abstract] [Full Text] [Related]
12. Placental circulating T cells: a novel, allogeneic car-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived car-T.
Ruggeri Barbaro N; Drashansky T; Tess K; Djedaini M; Hariri R; He S; van der Touw W; Karasiewicz K
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38684370
[TBL] [Abstract] [Full Text] [Related]
13. Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review.
Boretti A
Eur J Pharmacol; 2024 Jul; 974():176618. PubMed ID: 38679117
[TBL] [Abstract] [Full Text] [Related]
14. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (car) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
[TBL] [Abstract] [Full Text] [Related]
15. Breast Relapse of Pediatric B-Cell Acute Lymphoblastic Leukemia After car-T Therapy Detected by
Perrone E; Taralli S; Pagliara D; Larocca LM; Vinti L; Leccisotti L
Anticancer Res; 2024 May; 44(5):2243-2245. PubMed ID: 38677722
[TBL] [Abstract] [Full Text] [Related]
16. TANK Binding Kinase 1 Promotes BACH1 Degradation through Both Phosphorylation-Dependent and -Independent Mechanisms without Relying on Heme and FBXO22.
Liu L; Matsumoto M; Watanabe-Matsui M; Nakagawa T; Nagasawa Y; Pang J; Callens BKK; Muto A; Ochiai K; Takekawa H; Alam M; Nishizawa H; Shirouzu M; Shima H; Nakayama K; Igarashi K
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673728
[TBL] [Abstract] [Full Text] [Related]
17. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 car T Lymphocytes.
Khvorost D; Kendall B; Jazirehi AR
Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
[TBL] [Abstract] [Full Text] [Related]
18. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
[TBL] [Abstract] [Full Text] [Related]
19. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
[TBL] [Abstract] [Full Text] [Related]
20. Sequential CD7 car T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y; Zhang M; Yang T; Mo Z; Wei G; Jing R; Zhao H; Chen R; Zu C; Gu T; Xiao P; Hong R; Feng J; Fu S; Kong D; Xu H; Cui J; Huang S; Liang B; Yuan X; Cui Q; Guo H; Yu Y; Feng Y; Jin C; Ren J; Chang AH; Wang D; Huang H
N Engl J Med; 2024 Apr; 390(16):1467-1480. PubMed ID: 38657244
[TBL] [Abstract] [Full Text] [Related]
[Next]
